Technology
Valneva and LimmaTech secure Shigella vaccine fast track
Valneva and LimmaTech Biologics announced in October 2024 that they have been granted Fast Track designation by the United States FDA for Shigella4V
SK bioscience announces $3 million investment in FinaBio
SK bioscience announced in October 2024 that it has signed an agreement to acquire a stake in Fina Biosolutions (FinaBio) with a $3 million investment.
CEPI and CIDRAP advance coronavirus vaccine R&D roadmap
CEPI announced in October 2024 that the Centre for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota is to receive US$3.2
NIH funding for Orlance Enhanced Seasonal Influenza Vaccine
Orlance, Inc., announced in October 2024 that it has been awarded a National Institutions of Health (NIH) Fast Track Small Business Innovation Research
CEPI funding for University of Sheffield’s RNAbox process
In October 2024, CEPI announced that it is awarding funding of up to £3.7 million to support researchers at the University of Sheffield as they seek
Rokote and 3PBIOVIAN partner on FINCoVac 2.1 vaccine
3PBIOVIAN announced in September 2024 that it has been selected by Rokote Laboratories Finland Ltd. as CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate expressing a modified SARS-CoV-2 spike protein. The partnership aims to bring...
Vaxcyte reports positive topline results in study of VAX-31
Vaxcyte announced in September 2024 that its Phase I/II study of VAX-31, the 31-valent pneumococcal conjugate vaccine (PCV), has produced positive topline results. The study evaluates the safety, tolerability, and immunogenicity of the vaccine in healthy adults aged...
Positive booster data for Valneva and Pfizer Lyme candidate
In September 2024, Valneva and Pfizer announced positive immunogenicity and safety data from the VLA15-221 Phase II study investigating a second booster vaccination of their Lyme disease vaccine candidate. The vaccine, VLA15, is administered one year after receipt of...
Emergent secures FDA mpox expansion for ACAM2000
In August 2024, Emergent BioSolutions announced that the US FDA has approved the supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000 to include prevention of mpox disease in individuals determined to be at high risk for...
Workflow to detect falsified vaccines validated in study
Researchers from the University of Oxford shared their work in npj vaccines in August 2024, addressing the threat of “substandard and falsified vaccines” through a matrix-assisted laser desorption/ionisation-mass spectrometry (MALDI-MS) workflow. Their study validates...
Bharat Biotech launches HILLCHOL against cholera
Bharat Biotech announced the launch of HILLCHOL in August 2024, describing the novel single-strain oral cholera vaccine (OCV) as a “significant advancement in global health”. With only one manufacturer supplying OCVs globally, there is a yearly deficit of ~40 million...
Gates Foundation grant for Immorna RSV vaccine efforts
Immorna Biotherapeutics announced in August 2024 that it has received a grant, worth $3,800,000, from the Bill & Melinda Gates Foundation in support of the clinical development of JCXH-108. JCXH-108 is a Respiratory Syncytial Virus (RSV) vaccine based on Immorna’s...
Gonorrhoea antibody study supports vaccine development
Amid a rise in cases of antibiotic-resistant gonorrhoea, authors of a paper in Nature Communications present their research into the immune response gonorrhoea in the hope that it will enable the development of effective vaccines. They conducted a trial of 4CMenB in...
Touchlight supports Zika vaccine development with dbDNA
In August 2024 Touchlight announced that it is supplying its proprietary dbDNA to the University of Nottingham in support of the research and development of a next-generation DNA vaccine targeting Zika virus. The scientists at University of Nottingham are working on a...
Emergent pledges ACAM2000 doses for mpox response
Emergent BioSolutions announced in August 2024 that it is “proactively” working with WHO and the US government in response to the outbreak of mpox in Africa and has pledged to donate 50,000 doses of ACAM2000. The donation will be delivered with Direct Relief, a...
Shigella4V: the long journey and road ahead
This is a guest post, kindly authored by Giulia Balconi of Adjuvant Capital. Earlier this month, Valneva (NASDAQ: VALN) and LimmaTech Biologics announced a strategic partnership to accelerate the development of a quadrivalent vaccine against Shigella, known as...
Tonix shares mpox vaccine update after PHEIC declared
In August 2024 Tonix Pharmaceuticals “reiterated its commitment” to advancing the development of its live attenuated virus vaccine TNX-801 for the prevention of mpox and other infectious diseases. This comes after WHO declared that the spread of mpox in Africa...
SARS-CoV-2 “molecular dance” insights for vaccine efforts
A study by researchers at Yale School of Medicine (YSM), Northeastern University, and Rice University in Science (not open access) in August 2024 presents new views of an “intricate molecular dance” between human cells and SARS-CoV-2. Their findings could allow more...
ICMR and Panacea initiate DengiAll vaccine trial in India
The Indian Council of Medical Research (ICMR) and Panacea Biotec announced in August 2024 that they have initiated the "first-ever" Phase III clinical trial for a dengue vaccine in India. The trial will evaluate the efficacy of Panacea Biotec’s tetravalent dengue...
ABRYSVO: Pfizer’s positive safety and immunogenicity data
In August 2024 Pfizer announced positive top-line safety and immunogenicity results from substudy B of its ongoing Phase III clinical trial MONeT (RSV IMmunisatiON study for adulTs at higher risk of severe illness). The trial evaluates two doses of the ABRYSVO vaccine...
